KOLLTAN PHARMACEUTICALS, INC. Incentive Stock Option Agreement Granted Under 2008 Equity Incentive PlanIncentive Stock Option Agreement • August 8th, 2014 • Kolltan Pharmaceuticals Inc • Pharmaceutical preparations
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. THIRD AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • August 8th, 2014 • Kolltan Pharmaceuticals Inc • Pharmaceutical preparations • Connecticut
THIS THIRD AMENDED AND RESTATED LICENSE AGREEMENT (this “AGREEMENT”), dated as of March 14, 2013 (the “THIRD AMENDMENT EFFECTIVE DATE”), by and between YALE UNIVERSITY, a corporation organized and existing under and by virtue of a charter granted by the general assembly of the Colony and State of Connecticut and located in New Haven, Connecticut (“YALE”), and KOLLTAN PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware, and with principal offices located at 300 George Street, New Haven, CT 06511 (“LICENSEE”) is effective as of the THIRD AMENDMENT EFFECTIVE DATE.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSE AGREEMENT between LONZA SALES AG and KOLLTAN PHARMACEUTICALS, INC.License Agreement • August 8th, 2014 • Kolltan Pharmaceuticals Inc • Pharmaceutical preparations • New York
LONZA SALES AG, incorporated and registered in Switzerland, whose registered office is at Muenchensteinerstrasse 38, CH-4002, Basel, Switzerland, and
KOLLTAN PHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • August 8th, 2014 • Kolltan Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT, dated as of March 13, 2014 (this “Agreement”), by and among Kolltan Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and holders of the Company’s Series A Convertible Preferred Stock, $.001 par value (the “Series A Preferred Stock”), party hereto (the “Series A Holders”), Series B Convertible Preferred Stock, $.001 par value (the “Series B Preferred Stock”), party hereto (the “Series B Holders”), Series C Convertible Preferred Stock, $.001 par value (the “Series C Preferred Stock”), party hereto (the “Series C Holders”) and Series D Convertible Preferred Stock, $.001 par value (the “Series D Preferred Stock”), party hereto, listed on Exhibit A (together with certain other persons who become such as provided herein, the “Holders”), amends and restates the Amended and Restated Investor Rights Agreement, dated as of March 1, 2012, by and among the Company and the Holders, as previously amended and/or restated (the “Prior A
LEASE AGREEMENT BETWEEN WE GEORGE STREET, L.L.C. ("LANDLORD") AND KOLLTAN PHARMACEUTICALS INC. ("TENANT") LEASE AGREEMENT This Lease Agreement (the "Lease") is made and entered into as of the 5th day of January, 2009 (the "Effective Date") , by and...Lease • August 8th, 2014 • Kolltan Pharmaceuticals Inc • Pharmaceutical preparations
AMENDED AND RESTATED CONSULTING AGREEMENTConsulting Agreement • August 8th, 2014 • Kolltan Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS AMENDED AND RESTATED CONSULTING AGREEMENT, dated as of January 5, 2009 (this “Agreement”), by and between Kolltan Pharmaceuticals, Inc., a Delaware corporation (“Kolltan”), and Joseph Schlessinger, Ph.D. (the “Consultant”) amends and restates the Consulting Agreement, dated as of April 29, 2008, by and between Kolltan and the Consultant (the “Existing Agreement”).
Contract14 License Agreement • August 8th, 2014 • Kolltan Pharmaceuticals Inc • Pharmaceutical preparations • New York
KOLLTAN PHARMACEUTICALS, INC. REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 8th, 2014 • Kolltan Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS REGISTRATION RIGHTS AGREEMENT, dated as of February 8, 2008 (this “Agreement”), by and among Kolltan Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and holders of the Company’s Common Stock, $.001 par value (the “Common Stock”), listed on Exhibit A (together with certain other persons who become parties as provided herein, the “Holders”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSE AGREEMENT BETWEEN SPIROGEN DEVELOPMENTS LP & SPIROGEN SARL AND KOLLTAN PHARMACEUTICALS, INC.License Agreement • August 8th, 2014 • Kolltan Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (“Agreement”) is made and entered into, effective as of May 21, 2013 (“Effective Date”), by and between Spirogen Developments LP, a Bermuda limited partnership, having a registered office at Canon’s Court, 22 Victoria Street, Hamilton HM 11, Bermuda (“Spirogen LP”), and Spirogen SARL (Bermuda Branch), a Swiss limited liability company, having a place of business at Cumberland House, 1 Victoria Street, 5th Floor, Hamilton, HM12 Bermuda (“Spirogen SARL” and Spirogen LP collectively referred to herein as “Spirogen”), on the one hand, and Kolltan Pharmaceuticals, Inc. a Delaware corporation, having its principal place of business at 300 George Street, Suite #530, New Haven, CT 06511, U.S.A. (“Kolltan”), on the other hand. Kolltan and each of Spirogen are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSE AND OPTION AGREEMENT BY AND BETWEEN MEDIMMUNE, LLC AND BULLDOG PHARMACEUTICALS, INC.License and Option Agreement • August 8th, 2014 • Kolltan Pharmaceuticals Inc • Pharmaceutical preparations • New York
This License and Option Agreement (this “Agreement”) is entered into and made effective as of the 24th day of July, 2013 (the “Effective Date”), by and between MedImmune, LLC, a limited liability company organized and existing under the laws of Delaware, having a principal office located at One MedImmune Way, Gaithersburg, MD 20878 (“MedImmune”), and Bulldog Pharmaceuticals, Inc., a company organized and existing under the laws of the British Virgin Islands, having a registered office located at Midocean Chambers, Road Town, Tortola, British Virgin Islands (“Kolltan”). MedImmune and Kolltan are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. AMENDED AND RESTATED RESEARCH AGREEMENTAmended and Restated Research Agreement • August 8th, 2014 • Kolltan Pharmaceuticals Inc • Pharmaceutical preparations • Connecticut
This AMENDED AND RESTATED RESEARCH AGREEMENT (this “Agreement”) is entered into as of December 23, 2011 (the “Effective Date”), by and between Yale University, a non-profit corporation organized and existing under and by virtue of a special charter granted by the General Assembly of the Colony and State of Connecticut (the “University”), and KolltanPharmaceuticals, Inc., a Delaware corporation, having its principal offices at 300 George Street, Suite 530, New Haven, Connecticut 06511 (the “Sponsor”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. STANDSTILL AGREEMENTStandstill Agreement • August 8th, 2014 • Kolltan Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS STANDSTILL AGREEMENT, dated as of March 1, 2012 (this “Agreement”), by and among PHARMACEUTICALS, INC., a Delaware corporation (“Kolltan”), and GILEAD SCIENCES, INC., a Delaware corporation (the “Initial Investor”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double askterisks denote omissions. DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT between LONZA SALES AG and KOLLTAN PHARMACEUTICALS, INC.Development and Manufacturing Services Agreement • August 8th, 2014 • Kolltan Pharmaceuticals Inc • Pharmaceutical preparations • New York
KOLLTAN PHARMACEUTICALS, INC. Nonqualified Stock Option Agreement Granted Under 2008 Equity Incentive PlanNonqualified Stock • August 8th, 2014 • Kolltan Pharmaceuticals Inc • Pharmaceutical preparations
